Finishing off fibrils.
Bortezomib shows high activity in light chain amyloidosis. Responses occur rapidly and are seen in cardiac, renal, and hepatic disease. Toxicity in this fragile population is significant.
Gertz
Morie
M
Mayo Clinic, USA.